natgillin/translations-raw huggingface dataset:
Insulatard is often given in combination with fast-acting insulin products.
Insulatard se pogosto uporablja v kombinaciji s hitrodelujo imi insulinskimi insulini.
111 Using other medicines
Uporaba drugih zdravil
Talk to your doctor or pharmacist if you take or have recently taken any other medicines, even those not prescribed.
113 Posvetujte se z zdravnikom ali s farmacevtom, e jemljete ali ste pred kratkim jemali katerokoli drugo zdravilo, tudi e ste ga dobili brez recepta.
Follow their advice carefully.
Natan no upoštevajte dobljena navodila.
► In insulin infusion pumps ► If FlexPen is dropped, damaged or crushed there is a risk of leakage of insulin ► If it hasn’ t been stored correctly or been frozen (see 6 How to store Insulatard) ► If it’ s not uniformly white and cloudy when it’ s resuspended.
Shranjevanje zdravila Insulatard); e po resuspendiranju ni enakomerno belo in motno.
If you get any of these signs, eat glucose tablets or a high sugar snack (sweets, biscuits, fruit juice), then rest.
114 e se pojavi kateri od teh znakov, zaužijte tablete glukoze ali prigrizek, ki vsebuje veliko sladkorja (bonbone, piškote, sadni sok), in nato po ivajte. e utite, da se pojavlja hipa, si ne dajajte insulina.
If you inject yourself too often at the same site, fatty tissue under the skin at this site may shrink (lipoatrophy) or thicken (lipohypertrophy).
115 Spremembe na mestu injiciranja (lipodistrofija). e insulin prepogosto injicirate na isto mesto, se lahko podkožno maš evje na tem mestu skr i (lipoatrofija) ali zadebeli (lipohipertrofija).
Changing the site with each injection may help to prevent such skin changes.
Menjavanje injekcijskega mesta pri vsaki injekciji pomaga prepre iti takšne kožne spremembe. e na mestu injiciranja opazite ugreznjenost ali izbo enost kože, morate to povedati zdravniku ali medicinski sestri.
If you notice your skin pitting or thickening at the injection site, tell your doctor or nurse because these reactions can become more severe, or they may change the absorption of your insulin if you inject in such a site.
Takšne reakcije namre lahko postanejo hujše ali spremenijo absorpcijo insulina, e ga injicirate na takšno mesto.
Reactions (redness, swelling, itching) at the injection site may occur (local allergic reactions).
Pojavijo se lahko reakcije (pordelost, oteklost, srbenje) na mestu injiciranja (lokalne alergijske reakcije).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.
e kateri koli neželeni u inek postane resen ali e opazite kateri koli neželen u inek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika, medicinsko sestro ali farmacevta.
The FlexPen that is not being used is to be stored in a refrigerator (2°C - 8°C).
Peresnik FlexPen, ki ga ne uporabljate, shranjujte v hladilniku (med 2 °C in 8 °C).
The FlexPen that is being used, about to be used or carried as a spare is not to be kept in a refrigerator.
Peresnika FlexPen, ki ga uporabljate, ga boste pravkar uporabili ali ga imate pri sebi za rezervo, ne shranjujte v hladilniku!
After removing the FlexPen from the refrigerator it is recommended to let it reach room temperature before resuspending the insulin as instructed for the first time use.
Potem ko Insulatard FlexPen vzamete iz hladilnika, je priporo ljivo pustiti FlexPen, da doseže sobno temperaturo, preden insulin resuspendirate po navodilu za prvo uporabo.
See 3 How to use
Glejte poglavje 3, Kako uporabljati Insulatard.
Always keep the pen cap on your FlexPen when you’ re not using it in order to protect it from light.
Kadar peresnika FlexPen ne uporabljate, naj bo vedno pokrit s pokrov kom, da bo zaš iten pred svetlobo.
Insulatard must be protected from excessive heat and sunlight.
116 Insulatard je treba zaš ititi pred ezmerno toploto in son no svetlobo.
Not all packs may be marketed.
Izgled zdravila Insulatard in vsebina pakiranja Suspenzija za injiciranje je motna, bela, vodna suspenzija, opremljena v pakiranjih z 1, 5 ali 10 prednapolnjenih peresnikov po 3 ml (na trgu lahko ni vseh navedenih pakiranj).
Manufacturer The manufacturer can be identified by the batch number printed on the slip of the carton and on the label:
Izdelovalec Izdelovalca je mogo e ugotoviti po serijski številki, natisnjeni na etiketi škatle in na nalepki:
– If the second and third characters are W5, S6, P5, K7, or ZF Novo Nordisk A/ S, Novo Allé, DK-2880 Bagsværd, Denmark is the manufacturer
– e sta drugi in tretji znak W5, S6, P5, K7 ali ZF, je izdelovalec Novo Nordisk A/ S Novo Allé, DK- 2880 Bagsværd, Danska.
– If the second and third characters are H7 or T6 Novo Nordisk Production SAS, 45 Avenue d’ Orléans F-28002 Chartres, France is the manufacturer.
– e sta drugi in tretji znak H7 ali T6, je izdelovalec Novo Nordisk Production SAS, 45 Avenue d’ Orléans F- 28002 Chartres, Francija.
115 Introduction
117 Uvod
Please read the following instructions carefully before using your Insulatard FlexPen.
Preden uporabite Insulatard FlexPen, natan no preberite ta navodila
FlexPen is designed and tested to be used with NovoFine and NovoTwist disposable needles up to a length of 8 mm.
FlexPen je namenjen in preizkušen za uporabo z iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm.
Insulatard FlexPen Pen cap
Insulatard FlexPen pokrov ek peresnika
Rubber
vložek
12 units Glass
12 steklena
Cartridge
merilo
Residual
kazalnik izbirnik
Pointer
potisni
membrane
enot kroglica
Big outer
velik zunanji
Protective
zaš itna nalepka
needle cap needle cap
pokrov ek igle pokrov ek igle
Your FlexPen is designed to work accurately and safely.
Vaš FlexPen je izdelan za natan no in varno delovanje.
If it is dropped or crushed, there is a risk of damage and leakage of insulin.
Z njim morate ravnati previdno. e vam pade ali se zdrobi, obstaja nevarnost okvare in puš anja insulina.
You can clean the exterior of your FlexPen by wiping it with a medicinal swab.
Zunanjost peresnika FlexPen lahko o istite tako, da ga obrišete z medicinskim zložencem.
Preparing your Insulatard FlexPen
Priprava peresnika Insulatard FlexPen
Check the label to make sure that your FlexPen contains the correct type of insulin.
Preverite nalepko in se tako prepri ajte, da vaš FlexPen vsebuje pravo vrsto insulina.
A Let the insulin reach room temperature before you use it.
A Preden insulin uporabite, ga pustite, da doseže sobno temperaturo.
116 This makes it easier to resuspend.
118 Tako ga boste lažje resuspendirali.
Pull off the pen cap.
Snemite pokrov ek peresnika.
Repeat until the liquid appears uniformly white and cloudy.
Ponavljajte postopek vrtenja in obra anja peresnika, dokler ni teko ina enakomerno bela in motna.
For every following injection move the pen up and down between position 1 and 2 at least ten times until the liquid appears uniformly white and cloudy.
Za vsako naslednje injiciranje obrnite peresnik z vložkom vsaj desetkrat gor in dol med položajema 1 in 2, dokler ni teko ina enakomerno bela in motna.
If there are less than 12 units left, use a new FlexPen.
• Vedno preverite, ali je v vložku vsaj še 12 enot insulina, tako da je resuspendiranje mogo e. e je preostalo manj kot 12 enot, uporabite nov FlexPen.
C Remove the protective tab from a new disposable needle.
C Odstranite zaš itno nalepko z nove igle za enkratno uporabo.
D Pull off the big outer needle cap and keep it for later.
D Snemite veliki zunanji pokrov ek in ga shranite za pozneje.
E Pull off the inner needle cap and dispose of it.
E Snemite notranji pokrov ek igle in ga zavrzite.
• Always use a new needle for each injection to prevent contamination.
• Za vsako injiciranje uporabite novo iglo, da boste prepre ili kontaminacijo.
• To reduce the risk of unexpected needle sticks, never put the inner needle cap back on when you have removed it from the needle.
• Da boste zmanjšali tveganje za neželene vbode z iglo, nanjo nikdar znova ne nameš ajte notranjega pokrov ka igle, ki ste ga že sneli.
G Hold your FlexPen with the needle pointing upwards and tap the cartridge gently with your finger a few times to make any air bubbles collect at the top of the cartridge.
G Držite FlexPen tako, da je igla obrnjena navzgor, in s prstom nekajkrat rahlo potrkajte po vložku, da se bodo morebitni zra ni mehur ki zbrali na vrhu vložka.
H Keeping the needle upwards, press the push-button all the way in.
120 H Z iglo obrnjeno navzgor pritisnite potisni gumb do konca.
If not, change the needle and repeat the procedure no more than six times.
Na konici igle se mora pokazati kapljica insulina. e se ne, zamenjajte iglo in ponovite postopek, vendar ne ve kot šestkrat.
If a drop of insulin still does not appear, the pen is defective, and you must use a new one.
e se kapljica insulina še vedno ne pojavi, je peresnik pokvarjen in uporabiti morate novega.
You cannot select a dose larger than the number of units left in the cartridge.
Ne morete izbrati odmerka, ki bi bil ve ji od števila preostalih enot v vložku.
Insert the needle into your skin.
121 Zabodite iglo v kožo.
J Inject the dose by pressing the push-button all the way in until 0 lines up with the pointer.
J Odmerek injicirajte tako, da potisni gumb pritisnete do konca in se 0 uravna s kazalnikom.
L Lead the needle into the big outer needle cap without touching the big outer needle cap.
L Konico igle vstavite v veliki zunanji pokrov ek igle, ne da bi se ga dotaknili.
When the needle is covered, carefully push the big outer needle cap completely on and then unscrew the needle.
Ko je igla pokrita, veliki zunanji pokrov ek previdno do konca potisnite nanjo in iglo odvijte.
120 Dispose of it carefully and put the pen cap back on.
Pazljivo jo zavrzite in na peresnik znova namestite njegov pokrov ek.
• Always remove the needle after each injection and store your FlexPen without the needle attached.
• Po vsakem injciranju morate iglo odstraniti in zavre i, FlexPen pa shraniti brez nameš ene igle.
Otherwise, the liquid may leak out which can cause inaccurate dosing.
V nasprotnem primeru lahko teko ina izteka in to lahko povzro i neto no odmerjanje.
121
122
The Insulin Human Winthrop range is comprised of fast-acting insulin solutions (Insulin Human Winthrop Rapid and Insulin Human Winthrop Infusat) that contain soluble insulin, an intermediate-acting insulin suspension (Insulin Human Winthrop Basal) that contains isophane insulin, and combinations of fast- and intermediate- acting in various proportions (Insulin Human Winthrop Comb): • Insulin Human Winthrop Comb 15:
Paleta izdelkov Insulin Human Winthrop vključuje raztopine insulinov s hitrim delovanjem (Insulin Human Winthrop Rapid in Insulin Human Winthrop Infusat), ki vsebujejo topni insulin, suspenzije insulinov s srednje dolgim delovanjem (Insulin Human Winthrop Basal), ki vsebujejo insulin izofan, ter kombinacije insulina s hitrim in srednje dolgim delovanjem v različnih razmerjih (Insulin Human Winthrop Comb): • Insulin Human Winthrop Comb 15:
15% soluble insulin and 85% crystalline protamine insulin; • Insulin Human Winthrop Comb 25:
15% topnega insulina in 85% kristalnega protamin- insulina, • Insulin Human Winthrop Comb 25:
25% soluble insulin and 75% crystalline protamine insulin; • Insulin Human Winthrop Comb 50:
25% topnega insulina in 75% kristalnega protamin- insulina, • Insulin Human Winthrop Comb 50:
50% soluble insulin and 50% crystalline protamine insulin.
50% topnega insulina in 50% kristalnega protamin- insulina.
Insulin Human Winthrop is given by injection under the skin, generally in the abdominal wall (tummy) or the thigh, according to the doctor’ s recommendations.
Zdravilo Insulin Human Winthrop se daje z injekcijo pod kožo, običajno v trebušno steno ali stegno v skladu s priporočilom zdravnika.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Zdravnik za vsakega posameznika posebej določi zaželene koncentracije glukoze v krvi, vrsti zdravila Insulin 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. tested regularly to find the lowest effective dose.
Human Winthrop, ki ga je treba uporabiti, in čas uporabe injekcij ter jih prilagodi, da kar najbolje ustrezajo prehrani, telesni aktivnosti in življenjskemu slogu bolnika.
The active substance in Insulin Human Winthrop, insulin human, is produced by a method known as ‘ recombinant DNA technology’: it is made by a bacterium that has received a gene (DNA), which makes it able to produce insulin.
Zdravilno učinkovino v zdravilu Insulin Human Winthrop, humani insulin, proizvajajo z metodo, znano kot „ tehnologija rekombinantne DNK “, pri kateri bakterija prejme gen (DNK), s katerim lahko tvori insulin.
The studies measured the ‘ fasting’ blood glucose levels (measured when the patient had not eaten for at least eight hours), or the levels of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.
V okviru študij so merili raven glukoze na tešče (izmerjeno, ko bolnik najmanj osem ur ni zaužil hrane) ali koncentracijo snovi, imenovane glikozilirani hemoglobin (HbA1c), ki kaže, kako dobro je glukoza v krvi uravnana.
The Committee for Medicinal Products for Human Use (CHMP) decided that Insulin Human Winthrop’ s benefits are greater than its risks for the treatment of diabetes mellitus.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Insulin Human Winthrop pri zdravljenju sladkorne bolezni večje od z njim povezanih tveganj.
The European Commission granted a marketing authorisation valid throughout the EU for Insulin Human Winthrop to Sanofi-Aventis Deutschland GmbH on 17 January 2007.
Evropska komisija je dovoljenje za promet z zdravilom Insulin Human Winthrop, veljavno po vsej Evropski uniji, odobrila družbi Sanofi- Aventis Deutschland GmbH dne 17. januarja 2007.
OptiSet, solution for injection
OptiSet, raztopina za injiciranje
cartridge (glass) in disposable pen
vložek (steklen) v peresniku za enkratno uporabo
3 pens
3 peresniki
10 pens
10 peresnikov
OptiSet, suspension for injection
OptiSet, suspenzija za injiciranje
cartridges (glass) for OptiClik
vložek (steklen) za OptiClik
6 pre-filled pens for Optiset
6 peresnikov
9 pre-filled pens for Optiset
9 peresnikov
Insulin Human Winthrop Rapid 100 IU/ ml solution for injection in a vial
Insulin Human Winthrop Rapid 100 i. e. / ml raztopina za injiciranje v viali
Each ml contains 100 IU insulin human (equivalent to 3.5 mg).
En mililiter vsebuje 100 i. e. humanega insulina (kar ustreza 3, 5 mg).
Each vial contains 5 ml of solution for injection, equivalent to 500 IU insulin.
Vsaka viala vsebuje 5 ml raztopine za injiciranje, kar ustreza 500 i. e. insulina.
Human insulin is produced by recombinant DNA technology in Escherichia coli.
Humani insulin Insulin Human Winthropje pridobljen s tehnologijo rekombinantne DNA iz bakterij Escherichia coli.
Clear, colourless solution of water-like consistency.
Raztopina je bistra, brezbarvna in vodi podobne konsistence.
Insulin Human Winthrop Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and post-operative stabilisation in patients with diabetes mellitus.
Insulin Human Winthrop Rapid je primeren tudi za zdravljenje hiperglikemične kome in ketoacidoze ter za doseganje pred -, med - in pooperacijske stabilizacije pri bolnikih z diabetesom mellitusom.
The desired blood glucose levels, the insulin preparations to be used and the insulin dosage (doses and timings) must be determined individually and adjusted to suit the patient ’ s diet, physical activity and life-style.
Želeno koncentracijo glukoze v krvi, ustrezni pripravek insulina in njegovo odmerjanje (odmerke in čas uporabe) je treba določiti individualno in jih prilagoditi tako, da ustrezajo bolnikovi prehrani, telesni dejavnosti in življenjskemu slogu.
However, the average insulin requirement is often 0.5 to 1.0 IU per kg body weight per day.
Pogosto pa je povprečna potreba po insulinu od 0, 5 do 1, 0 i. e. na kilogram telesne mase na dan.
The basal metabolic requirement is 40% to 60% of the total daily requirement.
Osnovna presnovna potreba predstavlja od 40 do 60% celotne dnevne potrebe.
This regimen requires close monitoring (metabolic status, acid-base and electrolyte status, vital parameters etc.) in an intensive care unit or similar setting.
Takšna shema zahteva natančno kontrolo (presnovnega, acido- baznega in elektrolitskega ravnovesja, vitalnih parametrov idr.) v enoti za intenzivno nego ali podobnem okolju.
2 Transfer to Insulin Human Winthrop Rapid
Prehod na Insulin Human Winthrop Rapid
Dosage adjustment may be necessary when transferring patients from one insulin preparation to another.
2 Pri prehodu bolnika z enega insulinskega pripravka na drugega utegne biti potrebna prilagoditev odmerjanja.
This applies, for example, when transferring from:
To na primer velja pri prehodu z:
- an animal insulin (especially a bovine insulin) to human insulin,
- živalskega insulina (zlasti govejega) na humanega,
- one human insulin preparation to another,
- enega pripravka humanega insulina na drugega,
- a regimen with only regular insulin to one with a longer-acting insulin.
- sheme, ki je obsegala samo navadni insulin, na shemo, ki vključuje dlje delujoči insulin.
The need to adjust (e. g. reduce) the dose may become evident immediately after transfer.
Potreba po prilagoditvi (npr. zmanjšanju) odmerka se lahko pokaže takoj po prehodu.
Following transfer from an animal insulin to human insulin, dosage reduction may be required in particular in patients who
Po prehodu z živalskega insulina na humanega utegne biti potrebno zmanjšanje odmerka zlasti pri bolnikih, ki
- were previously already controlled on rather low blood glucose levels,
- so bili pred tem že urejeni na dokaj nizki koncentraciji glukoze v krvi,
- have a tendency to hypoglycaemia,
- so nagnjeni k hipoglikemiji,
- previously required high insulin doses due to the presence of insulin antibodies.
- so zaradi insulinskih protiteles prej potrebovali velike odmerke insulina.
- the patient's weight changes,
- spremeni bolnikova telesna masa,
- the patient's life-style changes,
- spremeni bolnikov življenjski slog,
- other circumstances arise that may promote an increased susceptibility to hypo- or
- pojavijo druge okoliščine, ki lahko sprožijo večjo nagnjenost k hipo - ali hiperglikemiji (glejte
hyperglycaemia (see section 4.4).
poglavje 4. 4).
Use in specific patient groups
Uporaba pri posebnih skupinah bolnikov
In patients with hepatic or renal impairment as well as in the elderly, insulin requirements may be diminished (see section 4.4).
Potreba po insulinu je lahko manjša pri bolnikih z okvaro jeter ali ledvic in pri starejših (glejte poglavje 4. 4).
Insulin Human Winthrop Rapid contains 100 IU of insulin per ml solution.
En mililiter raztopine Insulin Human Winthrop Rapid vsebuje 100 i. e. insulina.
Only injection syringes designed for this strength of insulin (100 IU per ml) are to be used.
Uporabljati se sme le injekcijske brizge, namenjene za to koncentracijo insulina (100 i. e. / ml).
The injection syringes must not contain any other medicinal product or residue (e. g. traces of heparin).
Injekcijske brizge ne smejo vsebovati nobenega drugega zdravila ali ostankov (npr. sledov heparina).
Insulin absorption and hence the blood glucose lowering effect of a dose may vary from one injection area to another (e. g. the abdominal wall compared with the thigh).
Absorpcija insulina – in s tem njegov hipoglikemični učinek – se lahko razlikuje od enega predela injiciranja do drugega (npr. trebušna stena v primerjavi s stegnom).
For further details on handling, see section 6.6.
Za podrobnosti o ravnanju z zdravilom glejte poglavje 6. 6.
Insulin Human Winthrop Rapid must not be used in external or implanted insulin pumps or in peristaltic pumps with silicone tubing.
Insulina Insulin Human Winthrop Rapid se ne sme uporabljati v zunanjih ali vsajenih insulinskih črpalkah ali v peristaltičnih črpalkah s silikonskimi cevkami.
In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered.
V primeru nezadostne urejenosti glukoze ali nagnjenosti k hiper - ali hipoglikemijam je treba pred spreminjanjem odmerka preveriti, ali bolnik upošteva predpisano shemo zdravljenja, mesta injiciranja, ustreznost načina injiciranja in vse druge pomembne dejavnike.
- in whom glycaemic control is markedly improved,
- ki se jim nadzor nad glikemijo občutno izboljša,
- in whom hypoglycaemia develops gradually,
- ki se jim hipoglikemija razvije počasi,
- who are elderly,
- ki so starejši,
- after transfer from animal insulin to human insulin,
- po prehodu z živalskega na humani insulin,
- in whom an autonomic neuropathy is present,
- ki imajo avtonomno nevropatijo,
- with a long history of diabetes,
- z dolgo anamnezo diabetesa,
- suffering from a psychiatric illness,
- s psihiatrično boleznijo,
- receiving concurrent treatment with certain other medicinal products (see section 4.5).
- ki sočasno prejemajo določena druga zdravila (glejte poglavje 4. 5).
4 Adherence of the patient to the dosage and dietary regimen, correct insulin administration and awareness of hypoglycaemia symptoms are essential to reduce the risk of hypoglycaemia.
Za zmanjšanje nevarnosti hipoglikemije mora bolnik nujno upoštevati shemo odmerjanja in načrt prehrane, pravilno aplicirati insulin in poznati simptome hipoglikemije.
- change in the injection area,
- sprememba predela injiciranja,
- improved insulin sensitivity (by, e. g., removal of stress factors),
- boljša občutljivost za insulin (npr. zaradi odprave dejavnikov stresa),
- unaccustomed, increased or prolonged physical activity,
- nevajena, večja ali dolgotrajnejša telesna dejavnost,
- intercurrent illness (e. g. vomiting, diarrhoea),
- sočasna bolezen (npr. bruhanje, driska),
- inadequate food intake,
- nezadostno uživanje hrane,
- missed meals,
- izpuščeni obroki,
- alcohol consumption,
- pitje alkohola,
- certain uncompensated endocrine disorders (e. g. in hypothyroidism and in anterior pituitary or
- določene nekompenzirane endokrine motnje (npr. hipotiroidizem, insuficienca sprednjega
adrenocortical insufficiency),
režnja hipofize ali insuficienca nadledvične skorje),
- concomitant treatment with certain other medicinal products.
- sočasno zdravljenje z določenimi drugimi zdravili.
Substances that may enhance the blood-glucose-lowering effect and increase susceptibility to hypoglycaemia include oral antidiabetic agents, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulphonamide antibiotics.
Med zdravili oz. snovmi, ki lahko stopnjujejo hipoglikemično delovanje in zvečajo nagnjenost k hipoglikemiji, so peroralni antidiabetiki, zaviralci angiotenzinske konvertaze (ACE), dizopiramid, fibrati, fluoksetin, zaviralci monoaminooksidaze (MAO), pentoksifilin, propoksifen, salicilati in sulfonamidni antibiotiki.
Substances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens (e. g. in oral contraceptives), phenothiazine derivatives, somatropin, sympathomimetic agents (e. g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, protease inhibitors and atypical antipsychotic medicinal products (e. g. olanzapine and clozapine).
Med zdravili oz. snovmi, ki lahko oslabijo hipoglikemično delovanje, so kortikosteroidi, danazol, diazoksid, diuretiki, glukagon, izoniazid, estrogeni in progestageni (npr. v peroralnih kontraceptivih), derivati fenotiazina, somatropin, simpatikomimetiki (npr. adrenalin, salbutamol, terbutalin), ščitnični hormoni, zaviralci proteaz in netipična antipsihotična zdravila (npr. olanzapin in klozapin).
Beta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood-glucose- lowering effect of insulin.
Zaviralci adrenergičnih receptorjev beta, klonidin, litijeve soli in alkohol lahko hipoglikemično delovanje insulina bodisi stopnjujejo ali oslabijo.